Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ART6043 in advanced or metastatic solid tumors
2023-509220-17-00Phase 2Authorised
- Sponsor
- Artios Pharma
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label trial of art6043 and olaparib in Nonhematologic neoplasms and breast cancer (3 arms), sponsored by Artios Pharma. Primary endpoint: Progression-free survival. Planned start Apr 2026; status: authorised.
02
Drugs
art6043olaparib
03
Conditions
Nonhematologic neoplasmsbreast cancer
Beyond the preview
Go deeper on 2023-509220-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509220-17-00.